Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Feb 18, 2021 11:14am
139 Views
Post# 32595651

RE:RE:RE:RE:CONTESSA PHARMA

RE:RE:RE:RE:CONTESSA PHARMA,,,,Hear ye hear ye,,,blockbuster junior biotech shares going for .89 cents CAD,,,,believe that if you will....,,isnt this just pitiable,,,shame on this inept management team from the top down,,,,this company continues to be nothing short of a gd ballbuster,,,,,and thats the best this team can produce after spending ruffly $500 milliion in research funding??,,,,,its a big GOOD GRIEF CHARLIE BROWN on this one!!!,,they have been such a major disappointment to their shareholders for years now!!!,,and possibly yet to get worse with dilution,,the market knows so!!
<< Previous
Bullboard Posts
Next >>